ClinicalTrials.gg
RecruitingNCT06802003ePredictAECOPDUpdated May 28, 2025

Predicting Acute Exacerbations of COPD Using Wearable Devices and Remote Monitoring Technology With AI/ML Models

An observational study in COPD and AE COPD, sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre. Recruiting at 1 site in Canada. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2025-05-28.

Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre · Observational

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Pulmonary Disease, Chronic Obstructive by McGill University Health Centre/Research Institute of the McGill University Health Centre — 2 open to participants now, 2 under way, none of them phase 3. Pulmonary Disease, Chronic Obstructive · McGill University Health Centre/Research Institute of the McGill University Health Centre.

Started
2025
with 3 others
Observational
6 of 14
2 open now
Registered
13th of 14
by date

Among the 14 studies in Pulmonary Disease, Chronic Obstructive by McGill University Health Centre/Research Institute of the McGill University Health Centre, this one is one of 4 that started in 2025, is one of 6 observational ones, and was the 13th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

2 of the 14 studies in Pulmonary Disease, Chronic Obstructive by McGill University Health Centre/Research Institute of the McGill University Health Centre are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Pulmonary Disease, Chronic Obstructive by McGill University Health Centre/Research Institute of the McGill University Health Centre, or all of them as a file.
02

Study summary

This study is aimed to collect real-time physiological data using two wearable devices (a biometric ring and a biometric wristband), daily lung mechanical measurements by a handheld oscillometer, and participant-reported symptoms in patients with COPD remotely from their home environment. The data will be used to train and validate artificial intelligence and machine learning (AI/ML) models to predict COPD exacerbations in advance of their actual occurrence. The data will also be used to test the new severity classification system for exacerbations of COPD, as well as to determine important relationships between physiological measurements from the wearable devices, the handheld oscillometer, the self-reported symptoms, and the tests performed at the baseline visit.

Read the detailed description

A single-site, prospective, observational cohort study to collect high-quality multidimensional data from the wearable/portable devices, as well as symptom and exacerbation data, in high-risk patients with frequent exacerbations in order to develop a COPD exacerbation predictive model.

03

Conditions studied

  • COPD
  • AE COPD

Keywords

  • acute exacerbation of COPD (AECOPD)
  • chronic obstructive pulmonary disease (COPD)
  • artificial intelligence/machine learning (AI/ML)
  • remote patient monitoring (RPM)
  • biometric wearable device
  • oscillometry
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with COPD with a documented history of frequent exacerbations.

While there is no specific method to estimate sample sizes for machine learning-based clinical research, based on two prior COPD studies measuring respiratory rate (RR) differences between stable-state and peak exacerbation phases, it was estimated that detecting a 4 breaths/min difference in RR (effect size 0.74) requires 17 prospectively collected exacerbation events, with alpha set to 0.05, power set to 0.8, and two-tailed analysis. Detecting a more subtle difference (i.e. 2 breaths/min; effect size 0.36) would require 63 events.

Assuming each participant experiences two exacerbations annually, 32 participants would meet these requirements. To account for the long observation period, the potential for non-events, and a 25% attrition rate, up to 50 participants will be recruited for this one-year study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males/females, age ≥ 40, former/current smokers with ≥10 pack-year smoking history
  • /FVC \< 0.7, with 80% \< FEV1 ≤50% (moderate, 'GOLD 2') 50% \< FEV1 ≤ 30% (severe, 'GOLD 3') or FEV1 \< 30% (very severe, 'GOLD 4')
  • History of 2 or more exacerbations in the preceding 12 months requiring , antibiotics, or both
  • Ability to provide
  • Ability to access internet at least once daily

Exclusion criteria

Exclusion Criteria:

  • No existing diagnosis
  • Any medical/cognitive/functional condition which renders inability to operate research equipment/devices, and/or to complete daily symptom response
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No

Interventions

  • DeviceBiometric wearable and handheld devices

    In this study, participants will be equipped with biometric wearable devices, i.e. ring and wristband, as well as with a handheld oscillometer, to measure their physiological parameters and lung mechanical changes (lung function).

06

What researchers measure

Primary outcomes

  1. Respiration

    Respiratory rate (RR) and respiratory rate variability (RRV) measured with wearable devices

    Time frame: Daily/nightly for 12 months

  2. Cardiovascular

    Heart rate (HR) and HR variability (HRV) measured with wearable devices

    Time frame: Daily/nightly for 12 months

  3. Oxygen level

    Blood oxygen saturation (SpO2) measured with wearable devices

    Time frame: Daily/nightly for 12 months

  4. Step count

    Parameter measured with wearable devices, related to activity.

    Time frame: Daily/nightly for 12 months

  5. Sleep duration

    Parameter measured with wearable devices.

    Time frame: Nightly for 12 months

  6. Rapid eye movement (REM) sleep

    Parameter measured with wearable devices.

    Time frame: Nightly for 12 months

  7. Deep sleep

    Parameter measured with wearable devices.

    Time frame: Nightly for 12 months

  8. Body temperature

    Peripheral body temperature measured with wearable devices

    Time frame: Nightly for 12 months

  9. Resistance at 5 Hz (R5)

    Parameter measured at 5 Hz frequency with handheld oscillometry, related to lung mechanics/function.

    Time frame: Daily for 12 months

  10. Reactance at 5 Hz (X5)

    Parameter measured at 5 Hz frequency with handheld oscillometry, related to lung mechanics/function.

    Time frame: Daily for 12 months

  11. Intra-breath difference between expiratory and inspiratory reactance (ΔXrs)

    Parameter measured with handheld oscillometry, related to lung mechanics/function.

    Time frame: Daily for 12 months

  12. Tidal volume (Vt)

    Parameter measured with handheld oscillometry, related to lung mechanics/function.

    Time frame: Daily for 12 months

  13. Respiratory flows

    Inspiratory and expiratory flows measured with handheld oscillometry, related to lung mechanics/function.

    Time frame: Daily for 12 months

  14. Respiratory rate (RR)

    Parameter measured with handheld oscillometry.

    Time frame: Daily for 12 months

  15. Minute ventilation (Ve)

    Parameter measured with handheld oscillometry, related to lung mechanics/function.

    Time frame: Daily for 12 months

  16. Heart rate (HR) prior oscillometry test

    Parameter measured with handheld oscillometry before performing oscillometry test.

    Time frame: Daily for 12 months

  17. Blood oxygen saturation (SpO2) prior oscillometry test

    Parameter measured with handheld oscillometry before performing oscillometry test.

    Time frame: Daily for 12 months

  18. Daily symptom questionnaire

    • Visual analog scale (VAS) scores for dyspnea, sputum volume, sputum purulence, cough, wheeze, and fatigue, scaled 0-10. Higher scores indicate worse symptoms.

    Time frame: Daily for 12 months

  19. Weekly exacerbation questionnaire

    • Self report on any exacerbation(s) which occurred in the preceding week and their date(s), whether/how the exacerbation was treated, and in what treatment setting.

    Time frame: Weekly for 12 months

  20. Calories

    Parameter measured with wearable devices, related to activity.

    Time frame: Daily/nightly for 12 months

  21. Metabolic equivalents

    Parameter measured with wearable devices, related to activity.

    Time frame: Daily/nightly for 12 months

  22. Movement intensity

    Parameter measured with wearable devices, related to activity.

    Time frame: Daily/nightly for 12 months

  23. Sleep efficiency

    Parameter measured with wearable devices.

    Time frame: Nightly for 12 months

  24. Sleep oncet

    Parameter measured with wearable devices.

    Time frame: Nightly for 12 months

  25. Sleep disturbance

    Parameter measured with wearable devices.

    Time frame: Nightly for 12 months

Secondary outcomes

  1. COPD Assessment Test (CAT)

    Validated COPD questionnaire consisting of 8 questions and scaled 0-40. Higher scores indicate the severity of disease impact.

    Time frame: Once (baseline visit)

  2. 6-Minute Walk Test (6MWT)

    Standard and validated assessment in COPD. Outcomes include distance walked as well as heart rate (HR), oxygen saturation (SpO2), and respiratory rate (RR) during the test. the 6MWT will be performed once at baseline while the participant is wearing the biometric wearable devices.

    Time frame: Once (baseline visit)

  3. System Usability Scale (SUS)

    Practical and reliable tool to determine the user experience with a variety of systems and devices. Scaled from 1-5, higher scores indicate better experience.

    Time frame: Through study completion, 1 year.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Due to data privacy regulations, individual participant data collected during this study is not publicly accessible. However, access to anonymized data may be granted upon evaluation by the trial management group. Additional documents will also be available upon inquiry. All requests should be directed to the corresponding author (BAR).

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for May 2026, 12 months after the start.

Of 469 non-industry observational studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 62. This study's planned 12 months is below that.

Counting every sponsor, half of 589 studies reached it within 26 months; a quarter within 14 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2025
First posted
Jan 30, 2025
StartActual
May 22, 2025
Primary completionEst.
May 31, 2026
CompletionEst.
Aug 31, 2026
Last update
May 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06802003
Collaborators
Restech Srl
Responsible party
Bryan A. Ross (Clinician-Scientist (RI-MUHC), Respirologist (MUHC), Assistant Professor (McGill University), McGill University Health Centre/Research Institute of the McGill University Health Centre) — Principal investigator
First posted
Jan 30, 2025
Start date
May 22, 2025
Primary completion
May 31, 2026 (estimated)
Completion
Aug 31, 2026 (estimated)
Last update
May 28, 2025

Study contacts

Bryan A. Ross, MD, MSc (Physiol), MSc (Epi)
Contact
bryan.ross@mcgill.ca
(514) 843-1465

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion